{"id":475619,"date":"2020-03-23T18:18:01","date_gmt":"2020-03-23T18:18:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=475619"},"modified":"2020-03-23T18:18:01","modified_gmt":"2020-03-23T18:18:01","slug":"stock-symbol-hot-biotech-curr-is-a-new-drug-delivery-company-that-improves-efficiency-safety-and-patient-experience","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/stock-symbol-hot-biotech-curr-is-a-new-drug-delivery-company-that-improves-efficiency-safety-and-patient-experience_475619.html","title":{"rendered":"Stock Symbol, Hot Biotech: CURR is a New Drug Delivery Company that Improves Efficiency, Safety and Patient Experience"},"content":{"rendered":"<div style=\"float:right;  width:250px; padding:8px 10px 10px 10px;\"><a href=\"https:\/\/www.abnewswire.com\/uploads\/1584951073.png\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Stock Symbol, Hot Biotech: CURR is a New Drug Delivery Company that Improves Efficiency, Safety and Patient Experience\" src=\"https:\/\/www.abnewswire.com\/uploads\/1584951073.png\" alt=\"Stock Symbol, Hot Biotech: CURR is a New Drug Delivery Company that Improves Efficiency, Safety and Patient Experience\" width=\"225\" height=\"225\" \/><\/a><\/div>\n<p style=\"text-align: justify;\"><span><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/uploads\/7a971acd7a612b5d0b0696ef731791ea.png\" alt=\"\" \/><\/span><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span>Patent on Oral Thin Films for ED Market in China.&nbsp;<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span>Vertically Integrated Drug Delivery Company with Proprietary Products.<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span>Major New Licensing Agreement for European Market.&nbsp;<\/span><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span>Licensing and Collaboration with Vanguard Scientific Systems.&nbsp;<\/span><\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span><br \/>CURE Pharmaceutical <\/span><span>(OTCQB: <\/span><span>CURR<\/span><span>) is a vertically integrated delivery and development company committed to improving drug efficiency, safety, and patient experience through its proprietary drug dosage forms and delivery systems. <\/span><span>CURR<\/span><span> has an FDA- and DEA- registered, GMP manufacturing facility and is a pioneering developer of CUREform&trade;, a patented drug delivery platform. CUREform&trade; includes CUREfilm<\/span><span><span>&reg;<\/span><\/span><span>, one of the most advanced oral thin films on the market today; microCURE&trade;, an innovative emulsion technology utilizing proprietary encapsulation techniques; and CUREpods&trade; a novel chewable delivery system.&nbsp;<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span>CURR<\/span><span> offers combined technologies that provide for immediate and controlled-release drug delivery of a wide range of active ingredients. <\/span><span>CURR<\/span><span> partners with biotech, pharmaceutical, and wellness companies worldwide and has positioned itself to advance numerous therapeutic categories with partnerships in the U.S.A, Canada, Israel, and other markets.<\/span><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span>Chinese Patent on Oral Thin Films to Treat Erectile Dysfunction<\/span><\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span>On March 17th <\/span><span>CURR<\/span><span> announced the allowance of Chinese Patent No. ZL201480039313.6 that covers the loading of high amounts of active drug on an oral thin film using its proprietary drug delivery systems, including its lead drug product,&nbsp;<\/span><span>CUREfilm Blue<\/span><span>&trade;, a soluble thin film for oral administration of sildenafil citrate (Viagra&trade;) to treat ED in China. The ED drug market is expected to reach USD&nbsp;$6.5 billion&nbsp;at a&nbsp;6%&nbsp;compound annual growth rate by 2025, according to&nbsp;<\/span><span>QYResearch<\/span><span>&#8230; Sildenafil is leading the ED drug market worldwide with more than half of all global sales.<\/span><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span>CURR Signs Licensing Agreement with ReLeaf Europe&nbsp;<\/span><\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span>On February 5<\/span><span><span>th<\/span><\/span><span>CURR<\/span><span> announced an exclusive licensing agreement with ReLeaf Europe, a leading pharmaceutical group for specialized products. The agreement grants ReLeaf Europe exclusive access to the <\/span><span>CURR<\/span><span> encapsulation technology for certain oral and topical products in the Netherlands.&nbsp;<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span>ReLeaf Europe is establishing a foothold in Holland &ndash; a market estimated to reach $2.6B by 2028. <\/span><span>CURR<\/span><span> will power several ReLeaf Europe products, including one sublingual tincture and two topical creams to be launched in 2020.<\/span><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\"><span>Licensing &amp; Collaboration Agreement with vanguard<\/span><span>&nbsp;<\/span><a rel=\"nofollow\" href=\"about:blank\"><span>Scientific Systems, Inc.<\/span><\/a><\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span>Vanguard is a premier provider of equipment, systems and performance solutions servicing the specialized botanical extraction industry. The license gives Vanguard the right to practice <\/span><span>CURR <\/span><span>patented extraction methods, providing customer confidence in choosing Vanguard&rsquo;s portfolio of extraction manufacturers.<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span>The&nbsp;specialized botanical extraction industry&nbsp;is poised&nbsp;to grow to $2.1 billion in 2020. <\/span><span>CURR<\/span><span> is strategically positioned with multiple high value assets and extremely well-placed marketing partners to optimize the company&rsquo;s earnings potential.&nbsp;<\/span><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><span>For more information on CURE Pharmaceutical <\/span><span>(OTCQB: <\/span><span>CURR<\/span><span>) visit: <\/span><a rel=\"nofollow\" href=\"about:blank\"><span>www.curepharmaceutical.com<\/span><\/a><span>. <br \/><\/span><\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/curepharmaceutical.com_55224.html\" rel=\"nofollow\">Cure Pharmaceuticals, Inc.<\/a><br \/><strong>Contact Person:<\/strong> Media Relations<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=stock-symbol-hot-biotech-curr-is-a-new-drug-delivery-company-that-improves-efficiency-safety-and-patient-experience\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> (805) 824-0410<br \/><strong>Address:<\/strong>1620 Beacon Place  <br \/><strong>City:<\/strong> Oxnard<br \/><strong>State:<\/strong> CA 93033<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.curepharmaceutical.com\/\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.curepharmaceutical.com\/<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.curepharmaceutical.com\/\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=stock-symbol-hot-biotech-curr-is-a-new-drug-delivery-company-that-improves-efficiency-safety-and-patient-experience\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Patent on Oral Thin Films for ED Market in China.&nbsp; Vertically Integrated Drug Delivery Company with Proprietary Products. Major New Licensing Agreement for European Market.&nbsp; Licensing and Collaboration with Vanguard Scientific Systems.&nbsp; CURE Pharmaceutical (OTCQB: CURR) is a vertically integrated &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/stock-symbol-hot-biotech-curr-is-a-new-drug-delivery-company-that-improves-efficiency-safety-and-patient-experience_475619.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[405,429,436,406,404],"tags":[],"class_list":["post-475619","post","type-post","status-publish","format-standard","hentry","category-Health-Medicine","category-Hospitality","category-India","category-Pharmaceuticals-Biotech","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/475619","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=475619"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/475619\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=475619"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=475619"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=475619"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}